BRAF-mutations in non-small cell lung cancer
2014; Elsevier BV; Volume: 84; Issue: 1 Linguagem: Inglês
10.1016/j.lungcan.2014.01.023
ISSN1872-8332
AutoresOdd Terje Brustugun, Asma Malik Khattak, Anette Kjoshagen Trømborg, Marzieh Beigi, Klaus Beiske, Marius Lund‐Iversen, Åslaug Helland,
Tópico(s)Lung Cancer Treatments and Mutations
ResumoAbstract Objectives Targeted therapies in non-small cell lung cancer (NSCLC) now also include inhibitors against mutated BRAF. We present clinicopathological characteristics of nearly one thousand unselected NSCLC patients tested for the targetable V600E/K BRAF-mutation. Material and methods NSCLC routinely tested for EGFR-mutations at Oslo University Hospital in the period February 2011–July 2013 were tested for V600E/K BRAF-mutations using a PCR-based method. Results We found a BRAF-mutation frequency of 1.7% in the total cohort of 979 patients, and 2.3% among 646 adenocarcinomas. One of the BRAF-positive samples was also KRAS-mutated, and one had an ALK-translocation. None of 231 squamous cell carcinomas were BRAF-mutated. The proportion of never-smokers among BRAF-positives was high (29%). Conclusion BRAF-mutation analysis should be part of the subtyping of non-squamous NSCLC.
Referência(s)